Supplementary Table 2 from Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Nikhil C. Munshi, Robin Joyce(Beth Israel Deaconess Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Lynne Uhl(Hadassah Medical Center), Paul G. Richardson(Harvard University), Jacob P. Laubach(Harvard University), Noopur Raje(Massachusetts General Hospital), Donald Küfe(Dana-Farber Cancer Institute), Jacob M. Rowe(Technion – Israel Institute of Technology), Yan Emily Yuan(Beth Israel Deaconess Medical Center), Baldev Vasir(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Irit Avivi(Tel Aviv Sourasky Medical Center), Lina Bisharat(Beth Israel Deaconess Medical Center), Tami Katz(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Bimalangshu R. Dey(Harvard University), Federico Campigotto(Bristol-Myers Squibb (United States)), Edie Weller(Boston Children's Hospital), James D. Levine(Beth Israel Deaconess Medical Center), Viki Held(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k